| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 182 | 2026 | 1980 | 14.870 |
Why?
|
| Pulmonary Artery | 65 | 2025 | 1134 | 4.800 |
Why?
|
| Hemodynamics | 59 | 2025 | 1119 | 3.960 |
Why?
|
| Ventricular Dysfunction, Right | 22 | 2026 | 248 | 3.130 |
Why?
|
| Heart Defects, Congenital | 39 | 2023 | 913 | 2.930 |
Why?
|
| Cardiac Catheterization | 43 | 2024 | 557 | 2.820 |
Why?
|
| Antihypertensive Agents | 30 | 2024 | 509 | 2.730 |
Why?
|
| Ventricular Function, Right | 24 | 2026 | 297 | 2.530 |
Why?
|
| Epoprostenol | 18 | 2022 | 131 | 2.240 |
Why?
|
| Arterial Pressure | 12 | 2025 | 135 | 2.170 |
Why?
|
| Child | 168 | 2026 | 22537 | 2.120 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2020 | 71 | 2.120 |
Why?
|
| Vasodilator Agents | 26 | 2025 | 331 | 2.070 |
Why?
|
| Familial Primary Pulmonary Hypertension | 30 | 2024 | 197 | 2.050 |
Why?
|
| Child, Preschool | 105 | 2026 | 11774 | 1.700 |
Why?
|
| Vascular Resistance | 39 | 2024 | 366 | 1.700 |
Why?
|
| Pulmonary Circulation | 36 | 2019 | 430 | 1.700 |
Why?
|
| Heart Ventricles | 23 | 2026 | 756 | 1.670 |
Why?
|
| Echocardiography | 26 | 2026 | 647 | 1.630 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 9 | 2022 | 35 | 1.620 |
Why?
|
| Nitric Oxide | 33 | 2021 | 897 | 1.590 |
Why?
|
| Ventricular Dysfunction, Left | 15 | 2022 | 390 | 1.480 |
Why?
|
| Ventricular Function, Left | 14 | 2024 | 538 | 1.460 |
Why?
|
| Endothelin Receptor Antagonists | 11 | 2019 | 62 | 1.430 |
Why?
|
| Adolescent | 115 | 2025 | 22281 | 1.290 |
Why?
|
| Infant | 85 | 2024 | 10022 | 1.280 |
Why?
|
| Receptors, Endothelin | 9 | 2003 | 50 | 1.240 |
Why?
|
| Pulmonary Wedge Pressure | 9 | 2020 | 67 | 1.220 |
Why?
|
| Vascular Stiffness | 13 | 2023 | 462 | 1.210 |
Why?
|
| Stroke Volume | 13 | 2025 | 648 | 1.180 |
Why?
|
| Predictive Value of Tests | 29 | 2026 | 2111 | 1.160 |
Why?
|
| Altitude Sickness | 4 | 2019 | 141 | 1.140 |
Why?
|
| Humans | 244 | 2026 | 144261 | 1.120 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2021 | 109 | 1.060 |
Why?
|
| Male | 163 | 2026 | 72035 | 1.010 |
Why?
|
| Altitude | 6 | 2019 | 473 | 0.990 |
Why?
|
| Lung | 27 | 2023 | 4108 | 0.970 |
Why?
|
| Magnetic Resonance Imaging, Cine | 11 | 2025 | 214 | 0.960 |
Why?
|
| Diagnostic Imaging | 3 | 2020 | 338 | 0.950 |
Why?
|
| Actigraphy | 2 | 2024 | 145 | 0.950 |
Why?
|
| Hypoplastic Left Heart Syndrome | 10 | 2024 | 120 | 0.940 |
Why?
|
| Female | 159 | 2026 | 77976 | 0.930 |
Why?
|
| Retrospective Studies | 74 | 2025 | 17009 | 0.900 |
Why?
|
| Tetralogy of Fallot | 6 | 2022 | 76 | 0.900 |
Why?
|
| Prognosis | 33 | 2026 | 4278 | 0.890 |
Why?
|
| Sulfonamides | 9 | 2019 | 580 | 0.880 |
Why?
|
| Echocardiography, Doppler | 12 | 2018 | 115 | 0.850 |
Why?
|
| Severity of Illness Index | 26 | 2025 | 2917 | 0.820 |
Why?
|
| Fontan Procedure | 9 | 2024 | 191 | 0.800 |
Why?
|
| Aorta | 13 | 2024 | 429 | 0.780 |
Why?
|
| Eisenmenger Complex | 4 | 2019 | 13 | 0.720 |
Why?
|
| Vasodilation | 11 | 2021 | 522 | 0.720 |
Why?
|
| Administration, Inhalation | 26 | 2021 | 574 | 0.700 |
Why?
|
| Endothelin-1 | 10 | 2012 | 184 | 0.680 |
Why?
|
| Age Factors | 21 | 2025 | 3313 | 0.670 |
Why?
|
| Blood Proteins | 2 | 2013 | 249 | 0.670 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2021 | 381 | 0.660 |
Why?
|
| Receptor, Endothelin B | 12 | 2012 | 48 | 0.650 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2026 | 3857 | 0.650 |
Why?
|
| Infant, Newborn | 49 | 2023 | 6424 | 0.650 |
Why?
|
| Case-Control Studies | 26 | 2025 | 3592 | 0.620 |
Why?
|
| Registries | 12 | 2024 | 2382 | 0.610 |
Why?
|
| Ventricular Remodeling | 3 | 2022 | 275 | 0.610 |
Why?
|
| Peptide Fragments | 6 | 2021 | 698 | 0.600 |
Why?
|
| Heart Transplantation | 13 | 2023 | 736 | 0.600 |
Why?
|
| Treatment Outcome | 44 | 2024 | 11643 | 0.600 |
Why?
|
| Prospective Studies | 26 | 2024 | 7970 | 0.580 |
Why?
|
| Endothelins | 7 | 2003 | 63 | 0.570 |
Why?
|
| Endpoint Determination | 2 | 2018 | 83 | 0.570 |
Why?
|
| Cardiovascular Agents | 3 | 2018 | 163 | 0.570 |
Why?
|
| Pulmonary Edema | 4 | 2019 | 106 | 0.570 |
Why?
|
| Hepatopulmonary Syndrome | 4 | 2018 | 23 | 0.540 |
Why?
|
| Phenylpropionates | 2 | 2022 | 27 | 0.540 |
Why?
|
| Pyridazines | 2 | 2022 | 57 | 0.530 |
Why?
|
| Oxygen | 13 | 2018 | 995 | 0.530 |
Why?
|
| Bronchopulmonary Dysplasia | 8 | 2023 | 410 | 0.520 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 346 | 0.520 |
Why?
|
| Critical Care | 2 | 2016 | 694 | 0.510 |
Why?
|
| Mitral Valve Stenosis | 2 | 2014 | 19 | 0.510 |
Why?
|
| Biomarkers | 18 | 2021 | 4254 | 0.500 |
Why?
|
| SOXF Transcription Factors | 3 | 2024 | 16 | 0.500 |
Why?
|
| Cause of Death | 2 | 2018 | 464 | 0.500 |
Why?
|
| Survival Rate | 17 | 2020 | 2088 | 0.490 |
Why?
|
| Mitral Valve | 3 | 2016 | 94 | 0.490 |
Why?
|
| MicroRNAs | 2 | 2020 | 700 | 0.480 |
Why?
|
| Models, Cardiovascular | 8 | 2020 | 195 | 0.480 |
Why?
|
| Cardiac Surgical Procedures | 7 | 2020 | 609 | 0.440 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 287 | 0.440 |
Why?
|
| Sheep | 20 | 2005 | 880 | 0.440 |
Why?
|
| Sildenafil Citrate | 7 | 2017 | 60 | 0.440 |
Why?
|
| Abnormalities, Multiple | 3 | 2010 | 197 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 2026 | 0.430 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 6 | 2022 | 219 | 0.430 |
Why?
|
| Image Enhancement | 2 | 2015 | 199 | 0.420 |
Why?
|
| Exercise Test | 7 | 2019 | 634 | 0.420 |
Why?
|
| Hypoxia | 12 | 2009 | 1199 | 0.420 |
Why?
|
| Ketamine | 1 | 2015 | 132 | 0.420 |
Why?
|
| Myocardial Contraction | 6 | 2020 | 298 | 0.410 |
Why?
|
| Pediatrics | 8 | 2018 | 1112 | 0.410 |
Why?
|
| Dipyridamole | 6 | 1998 | 28 | 0.410 |
Why?
|
| Prostaglandins I | 1 | 2013 | 1 | 0.410 |
Why?
|
| Protein Precursors | 6 | 2020 | 136 | 0.400 |
Why?
|
| Disease Management | 5 | 2019 | 643 | 0.400 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.400 |
Why?
|
| Follow-Up Studies | 23 | 2021 | 5389 | 0.400 |
Why?
|
| Connective Tissue Diseases | 2 | 2011 | 84 | 0.390 |
Why?
|
| Risk Assessment | 16 | 2019 | 3637 | 0.390 |
Why?
|
| Disease Progression | 12 | 2024 | 2840 | 0.390 |
Why?
|
| Dexmedetomidine | 1 | 2013 | 44 | 0.390 |
Why?
|
| Pulmonary Ventilation | 1 | 2013 | 83 | 0.390 |
Why?
|
| Blood Flow Velocity | 14 | 2024 | 413 | 0.380 |
Why?
|
| Down Syndrome | 4 | 2022 | 534 | 0.380 |
Why?
|
| Norwood Procedures | 2 | 2024 | 29 | 0.380 |
Why?
|
| Blood Pressure | 19 | 2019 | 1759 | 0.380 |
Why?
|
| Fetus | 12 | 2018 | 803 | 0.370 |
Why?
|
| Carbolines | 1 | 2012 | 35 | 0.360 |
Why?
|
| Sulfones | 5 | 2014 | 127 | 0.360 |
Why?
|
| Heart Atria | 4 | 2021 | 144 | 0.350 |
Why?
|
| Atrial Function, Right | 4 | 2025 | 14 | 0.350 |
Why?
|
| Phosphodiesterase Inhibitors | 5 | 2010 | 73 | 0.350 |
Why?
|
| Aorta, Thoracic | 4 | 2021 | 286 | 0.350 |
Why?
|
| Cardiology | 4 | 2017 | 353 | 0.350 |
Why?
|
| Iloprost | 2 | 2010 | 44 | 0.340 |
Why?
|
| Aortic Coarctation | 3 | 2018 | 79 | 0.340 |
Why?
|
| Calcium Channel Blockers | 3 | 2016 | 165 | 0.340 |
Why?
|
| Pulmonary Veins | 4 | 2023 | 105 | 0.340 |
Why?
|
| Heart Failure | 7 | 2023 | 2314 | 0.330 |
Why?
|
| Exercise Tolerance | 6 | 2016 | 283 | 0.320 |
Why?
|
| Young Adult | 28 | 2021 | 13990 | 0.320 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 2 | 2021 | 22 | 0.320 |
Why?
|
| Heterotaxy Syndrome | 1 | 2010 | 14 | 0.320 |
Why?
|
| Cardiac Output | 7 | 2017 | 179 | 0.310 |
Why?
|
| Piperazines | 5 | 2014 | 380 | 0.310 |
Why?
|
| Bacteremia | 2 | 2009 | 221 | 0.310 |
Why?
|
| Heart Septal Defects | 2 | 2026 | 13 | 0.300 |
Why?
|
| Quality of Life | 2 | 2020 | 3166 | 0.300 |
Why?
|
| Cohort Studies | 11 | 2024 | 5935 | 0.300 |
Why?
|
| Survival Analysis | 10 | 2020 | 1382 | 0.300 |
Why?
|
| Portal Vein | 1 | 2010 | 114 | 0.290 |
Why?
|
| Principal Component Analysis | 3 | 2024 | 197 | 0.290 |
Why?
|
| Hospitalization | 2 | 2019 | 2424 | 0.290 |
Why?
|
| Tricuspid Valve | 4 | 2017 | 41 | 0.290 |
Why?
|
| Risk Factors | 21 | 2025 | 10699 | 0.280 |
Why?
|
| Systole | 8 | 2022 | 178 | 0.280 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 1487 | 0.280 |
Why?
|
| Heart Neoplasms | 1 | 2008 | 55 | 0.280 |
Why?
|
| T-Box Domain Proteins | 2 | 2019 | 106 | 0.270 |
Why?
|
| Endothelin B Receptor Antagonists | 2 | 2005 | 12 | 0.270 |
Why?
|
| Time Factors | 20 | 2024 | 7155 | 0.270 |
Why?
|
| Vasoconstriction | 5 | 2004 | 217 | 0.270 |
Why?
|
| Age of Onset | 4 | 2020 | 536 | 0.270 |
Why?
|
| Colorado | 10 | 2020 | 4562 | 0.270 |
Why?
|
| Cysts | 1 | 2008 | 111 | 0.270 |
Why?
|
| Animals, Newborn | 5 | 2004 | 901 | 0.270 |
Why?
|
| Catheterization, Central Venous | 1 | 2009 | 122 | 0.260 |
Why?
|
| Reproducibility of Results | 12 | 2025 | 3403 | 0.260 |
Why?
|
| Anastomosis, Surgical | 4 | 2021 | 157 | 0.260 |
Why?
|
| Hypertension, Portal | 3 | 2018 | 66 | 0.260 |
Why?
|
| Electrocardiography | 4 | 2023 | 660 | 0.250 |
Why?
|
| Fetal Diseases | 3 | 2003 | 191 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 850 | 0.250 |
Why?
|
| Oxygen Consumption | 4 | 2017 | 724 | 0.250 |
Why?
|
| Adult | 28 | 2023 | 40262 | 0.240 |
Why?
|
| Receptor, Endothelin A | 7 | 2012 | 63 | 0.240 |
Why?
|
| Global Health | 5 | 2019 | 394 | 0.240 |
Why?
|
| Ontario | 4 | 2020 | 96 | 0.240 |
Why?
|
| Infant, Premature, Diseases | 2 | 2019 | 111 | 0.240 |
Why?
|
| Tunica Intima | 2 | 2007 | 78 | 0.240 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2023 | 360 | 0.240 |
Why?
|
| Regional Blood Flow | 5 | 2021 | 512 | 0.240 |
Why?
|
| Perfusion Imaging | 3 | 2024 | 65 | 0.230 |
Why?
|
| Morbidity | 3 | 2019 | 323 | 0.230 |
Why?
|
| Cytokines | 2 | 2012 | 2061 | 0.230 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2005 | 4 | 0.230 |
Why?
|
| 1,4-alpha-Glucan Branching Enzyme | 1 | 2005 | 4 | 0.230 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 337 | 0.230 |
Why?
|
| Pulse Wave Analysis | 4 | 2018 | 245 | 0.220 |
Why?
|
| Diastole | 7 | 2022 | 141 | 0.220 |
Why?
|
| Interleukin-6 | 3 | 2021 | 780 | 0.220 |
Why?
|
| Multimodal Imaging | 1 | 2026 | 124 | 0.220 |
Why?
|
| Animals | 41 | 2019 | 38030 | 0.220 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 90 | 0.220 |
Why?
|
| Feasibility Studies | 6 | 2024 | 1087 | 0.210 |
Why?
|
| Home Nursing | 2 | 2003 | 23 | 0.210 |
Why?
|
| Pulmonary Valve Insufficiency | 2 | 2022 | 48 | 0.210 |
Why?
|
| Patient Selection | 2 | 2019 | 719 | 0.210 |
Why?
|
| Transposition of Great Vessels | 2 | 2017 | 41 | 0.210 |
Why?
|
| Acetamides | 1 | 2024 | 37 | 0.210 |
Why?
|
| Gene Deletion | 2 | 2019 | 387 | 0.200 |
Why?
|
| Infusions, Intravenous | 5 | 2019 | 423 | 0.200 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2024 | 251 | 0.200 |
Why?
|
| Pyrazines | 1 | 2024 | 92 | 0.200 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 64 | 0.200 |
Why?
|
| Prostaglandins | 5 | 2022 | 94 | 0.200 |
Why?
|
| Hypertrophy, Right Ventricular | 7 | 2020 | 150 | 0.200 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1050 | 0.200 |
Why?
|
| Pyrimidines | 2 | 2019 | 532 | 0.200 |
Why?
|
| Linear Models | 8 | 2016 | 850 | 0.200 |
Why?
|
| Lymphokines | 1 | 2003 | 130 | 0.200 |
Why?
|
| Lung Transplantation | 5 | 2019 | 338 | 0.200 |
Why?
|
| Muscle, Smooth, Vascular | 6 | 2012 | 452 | 0.190 |
Why?
|
| Persistent Fetal Circulation Syndrome | 8 | 2015 | 138 | 0.190 |
Why?
|
| Drug Administration Schedule | 6 | 2020 | 778 | 0.190 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2023 | 19 | 0.190 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 3 | 2021 | 17 | 0.190 |
Why?
|
| Piperidines | 2 | 2004 | 217 | 0.190 |
Why?
|
| Heart Rate | 4 | 2024 | 849 | 0.190 |
Why?
|
| Oligopeptides | 2 | 2004 | 268 | 0.190 |
Why?
|
| Cyclic GMP | 3 | 2019 | 92 | 0.190 |
Why?
|
| Stress, Mechanical | 8 | 2019 | 494 | 0.190 |
Why?
|
| Animals, Genetically Modified | 4 | 2005 | 250 | 0.180 |
Why?
|
| Rats | 13 | 2013 | 5592 | 0.180 |
Why?
|
| Ventricular Function | 2 | 2021 | 57 | 0.180 |
Why?
|
| Angiostatic Proteins | 1 | 2021 | 4 | 0.180 |
Why?
|
| Postoperative Complications | 5 | 2020 | 2916 | 0.180 |
Why?
|
| Exercise | 2 | 2024 | 2193 | 0.180 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 5813 | 0.180 |
Why?
|
| Aortic Valve Stenosis | 2 | 2019 | 248 | 0.180 |
Why?
|
| Drug Approval | 2 | 2019 | 89 | 0.170 |
Why?
|
| Walk Test | 2 | 2024 | 80 | 0.170 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2002 | 50 | 0.170 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 19 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 964 | 0.170 |
Why?
|
| Incidence | 7 | 2017 | 2870 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 427 | 0.170 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 83 | 0.170 |
Why?
|
| Nitric Oxide Synthase | 6 | 2002 | 235 | 0.170 |
Why?
|
| Hyaline Membrane Disease | 2 | 1998 | 20 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2002 | 2829 | 0.170 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.170 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 4556 | 0.170 |
Why?
|
| Endothelin A Receptor Antagonists | 3 | 2012 | 26 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2020 | 8 | 0.170 |
Why?
|
| ROC Curve | 3 | 2018 | 612 | 0.170 |
Why?
|
| Purines | 5 | 2014 | 187 | 0.170 |
Why?
|
| Double Outlet Right Ventricle | 2 | 2012 | 9 | 0.160 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 96 | 0.160 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 44 | 0.160 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 1322 | 0.160 |
Why?
|
| Analysis of Variance | 4 | 2018 | 1304 | 0.160 |
Why?
|
| Pulmonary Gas Exchange | 3 | 2013 | 119 | 0.160 |
Why?
|
| Hernia, Diaphragmatic | 4 | 2008 | 67 | 0.160 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 236 | 0.150 |
Why?
|
| Heart Function Tests | 1 | 2019 | 59 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 285 | 0.150 |
Why?
|
| Respiration, Artificial | 6 | 2017 | 707 | 0.150 |
Why?
|
| Alprostadil | 2 | 2003 | 29 | 0.150 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2019 | 16 | 0.150 |
Why?
|
| Observer Variation | 3 | 2018 | 354 | 0.150 |
Why?
|
| Thrombosis | 1 | 2003 | 393 | 0.150 |
Why?
|
| Jacobsen Distal 11q Deletion Syndrome | 2 | 2009 | 2 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2017 | 62 | 0.150 |
Why?
|
| Genetic Variation | 3 | 2019 | 982 | 0.150 |
Why?
|
| Dilatation, Pathologic | 3 | 2018 | 62 | 0.150 |
Why?
|
| Research Subjects | 1 | 2019 | 41 | 0.150 |
Why?
|
| HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.150 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1996 | 56 | 0.150 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 36 | 0.150 |
Why?
|
| Scurvy | 1 | 2019 | 17 | 0.140 |
Why?
|
| Anatomy | 1 | 2019 | 30 | 0.140 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 46 | 0.140 |
Why?
|
| Catheters, Indwelling | 2 | 2009 | 96 | 0.140 |
Why?
|
| Aortic Diseases | 1 | 2020 | 124 | 0.140 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 87 | 0.140 |
Why?
|
| Tadalafil | 2 | 2022 | 6 | 0.140 |
Why?
|
| Heart Bypass, Right | 1 | 2018 | 17 | 0.140 |
Why?
|
| Gene Expression | 3 | 2003 | 1487 | 0.140 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2018 | 52 | 0.140 |
Why?
|
| Reference Values | 7 | 2017 | 797 | 0.140 |
Why?
|
| Thermodilution | 1 | 2017 | 15 | 0.130 |
Why?
|
| Turner Syndrome | 1 | 2018 | 63 | 0.130 |
Why?
|
| Infant, Premature | 5 | 2023 | 611 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 3 | 2011 | 309 | 0.130 |
Why?
|
| Patients | 1 | 2019 | 178 | 0.130 |
Why?
|
| Gestational Age | 8 | 2004 | 975 | 0.130 |
Why?
|
| Algorithms | 3 | 2016 | 1834 | 0.130 |
Why?
|
| Blood Pressure Determination | 3 | 2008 | 142 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2017 | 24 | 0.130 |
Why?
|
| Pulmonary Valve | 1 | 2019 | 101 | 0.130 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2018 | 91 | 0.130 |
Why?
|
| Research Personnel | 1 | 2019 | 183 | 0.130 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2012 | 266 | 0.130 |
Why?
|
| Vasomotor System | 4 | 2006 | 46 | 0.130 |
Why?
|
| Vascular Capacitance | 1 | 2016 | 4 | 0.130 |
Why?
|
| Blotting, Northern | 4 | 2002 | 204 | 0.130 |
Why?
|
| Heart Failure, Systolic | 1 | 2017 | 27 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 405 | 0.130 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2017 | 73 | 0.130 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 15 | 0.130 |
Why?
|
| Blood Vessels | 2 | 2013 | 171 | 0.130 |
Why?
|
| Exome | 1 | 2018 | 227 | 0.130 |
Why?
|
| Travel | 1 | 2018 | 136 | 0.130 |
Why?
|
| Anticoagulants | 3 | 2011 | 721 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2016 | 14 | 0.120 |
Why?
|
| United States | 13 | 2025 | 15876 | 0.120 |
Why?
|
| Administration, Oral | 5 | 2020 | 847 | 0.120 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 204 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 780 | 0.120 |
Why?
|
| Proteomics | 2 | 2014 | 1191 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 160 | 0.120 |
Why?
|
| Hypertension | 1 | 2005 | 1254 | 0.120 |
Why?
|
| Endothelin-3 | 1 | 1996 | 3 | 0.120 |
Why?
|
| Arteries | 1 | 2018 | 258 | 0.120 |
Why?
|
| United States Food and Drug Administration | 2 | 2017 | 203 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2017 | 221 | 0.120 |
Why?
|
| Health Information Systems | 1 | 2016 | 16 | 0.120 |
Why?
|
| Forecasting | 1 | 2018 | 388 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 557 | 0.120 |
Why?
|
| Coronary Care Units | 1 | 2016 | 26 | 0.120 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 72 | 0.120 |
Why?
|
| Nitrous Oxide | 1 | 2016 | 35 | 0.120 |
Why?
|
| Echinococcosis, Pulmonary | 1 | 2015 | 7 | 0.120 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1998 | 186 | 0.120 |
Why?
|
| Growth Disorders | 1 | 2016 | 86 | 0.110 |
Why?
|
| Endothelium, Vascular | 3 | 2021 | 963 | 0.110 |
Why?
|
| Mitral Valve Prolapse | 1 | 1995 | 9 | 0.110 |
Why?
|
| Anesthetics | 1 | 2016 | 99 | 0.110 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 115 | 0.110 |
Why?
|
| Fibroblasts | 3 | 2013 | 1032 | 0.110 |
Why?
|
| Elasticity | 7 | 2015 | 184 | 0.110 |
Why?
|
| Chronic Disease | 8 | 2010 | 1812 | 0.110 |
Why?
|
| Heart | 1 | 2019 | 633 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2022 | 1044 | 0.110 |
Why?
|
| Hemorrhage | 2 | 2019 | 809 | 0.110 |
Why?
|
| Body Height | 1 | 2016 | 202 | 0.110 |
Why?
|
| Ductus Arteriosus | 5 | 2000 | 72 | 0.110 |
Why?
|
| Computer Systems | 1 | 2014 | 56 | 0.110 |
Why?
|
| Peptides, Cyclic | 4 | 1998 | 275 | 0.110 |
Why?
|
| Probability | 4 | 2008 | 308 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1995 | 121 | 0.110 |
Why?
|
| Cardiomegaly | 3 | 2008 | 172 | 0.110 |
Why?
|
| Angina Pectoris, Variant | 1 | 1994 | 3 | 0.100 |
Why?
|
| Dogs | 1 | 2015 | 437 | 0.100 |
Why?
|
| Ventricular Septum | 2 | 2015 | 8 | 0.100 |
Why?
|
| Ebstein Anomaly | 1 | 1993 | 7 | 0.100 |
Why?
|
| Netherlands | 1 | 2013 | 82 | 0.100 |
Why?
|
| Contrast Media | 1 | 2017 | 486 | 0.100 |
Why?
|
| Health Policy | 1 | 2017 | 398 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2018 | 1484 | 0.100 |
Why?
|
| Analgesics | 1 | 2015 | 228 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 379 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 97 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 919 | 0.100 |
Why?
|
| Lung Diseases | 4 | 2016 | 787 | 0.100 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 284 | 0.100 |
Why?
|
| Pain | 1 | 2019 | 777 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2015 | 227 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1559 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2008 | 523 | 0.100 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 80 | 0.100 |
Why?
|
| Biopsy | 1 | 2016 | 1075 | 0.100 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2012 | 46 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 72 | 0.090 |
Why?
|
| Shear Strength | 4 | 2018 | 72 | 0.090 |
Why?
|
| Equipment Contamination | 2 | 2009 | 71 | 0.090 |
Why?
|
| Thromboembolism | 2 | 2005 | 125 | 0.090 |
Why?
|
| Endostatins | 2 | 2021 | 10 | 0.090 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1264 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 284 | 0.090 |
Why?
|
| Ultrasonography, Doppler | 3 | 2012 | 126 | 0.090 |
Why?
|
| Arteritis | 1 | 2012 | 25 | 0.090 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 1995 | 235 | 0.090 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 60 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2009 | 221 | 0.090 |
Why?
|
| Decision Making | 1 | 2019 | 974 | 0.090 |
Why?
|
| Biomechanical Phenomena | 4 | 2018 | 842 | 0.090 |
Why?
|
| Mutation | 3 | 2019 | 4085 | 0.090 |
Why?
|
| Research Design | 2 | 2015 | 1129 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2015 | 509 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1533 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2018 | 582 | 0.080 |
Why?
|
| Bronchodilator Agents | 2 | 2005 | 182 | 0.080 |
Why?
|
| In Situ Hybridization | 2 | 2002 | 319 | 0.080 |
Why?
|
| Syndrome | 3 | 2024 | 380 | 0.080 |
Why?
|
| Chromosome Mapping | 2 | 2009 | 509 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 355 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2012 | 309 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2002 | 204 | 0.080 |
Why?
|
| Phagocytes | 1 | 2011 | 81 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1705 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 257 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2011 | 247 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2010 | 7 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2015 | 382 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2011 | 148 | 0.080 |
Why?
|
| Mesoderm | 1 | 2011 | 150 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2010 | 540 | 0.080 |
Why?
|
| Liver Cirrhosis | 2 | 2018 | 288 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2012 | 195 | 0.080 |
Why?
|
| Natriuretic Peptides | 1 | 2009 | 9 | 0.080 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2009 | 26 | 0.080 |
Why?
|
| Proteome | 1 | 2014 | 514 | 0.080 |
Why?
|
| Liver Transplantation | 3 | 2018 | 822 | 0.080 |
Why?
|
| Acetylcholine | 4 | 2001 | 204 | 0.080 |
Why?
|
| Palliative Care | 4 | 2018 | 996 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2020 | 49 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2017 | 329 | 0.080 |
Why?
|
| Gram-Positive Bacteria | 1 | 2009 | 47 | 0.070 |
Why?
|
| Uncertainty | 1 | 2010 | 144 | 0.070 |
Why?
|
| Heart Diseases | 2 | 2011 | 349 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 893 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 51 | 0.070 |
Why?
|
| Primary Graft Dysfunction | 1 | 2009 | 35 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2009 | 81 | 0.070 |
Why?
|
| Neurogranin | 1 | 2008 | 2 | 0.070 |
Why?
|
| Heart Septum | 1 | 2008 | 28 | 0.070 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 69 | 0.070 |
Why?
|
| Perioperative Care | 2 | 2012 | 230 | 0.070 |
Why?
|
| Home Infusion Therapy | 1 | 2008 | 4 | 0.070 |
Why?
|
| Pregnancy | 10 | 2012 | 7180 | 0.070 |
Why?
|
| Monocrotaline | 2 | 2005 | 32 | 0.070 |
Why?
|
| Prevalence | 4 | 2018 | 2815 | 0.070 |
Why?
|
| Respiratory Function Tests | 2 | 2008 | 546 | 0.070 |
Why?
|
| Nitroarginine | 6 | 2001 | 57 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2011 | 535 | 0.070 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2008 | 40 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 225 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2016 | 2420 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2003 | 307 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 57 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2023 | 2730 | 0.060 |
Why?
|
| Time | 2 | 2005 | 86 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 729 | 0.060 |
Why?
|
| Inflammation | 3 | 2013 | 2877 | 0.060 |
Why?
|
| Cognition | 1 | 2015 | 1258 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 1983 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2023 | 151 | 0.060 |
Why?
|
| Infusions, Subcutaneous | 2 | 2019 | 24 | 0.060 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2009 | 194 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2007 | 37 | 0.060 |
Why?
|
| Safety | 2 | 2005 | 355 | 0.060 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2005 | 11 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2013 | 1497 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 909 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 2134 | 0.060 |
Why?
|
| Logistic Models | 4 | 2013 | 2104 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 2359 | 0.060 |
Why?
|
| Amylopectin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2007 | 139 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2003 | 59 | 0.060 |
Why?
|
| Middle Aged | 8 | 2020 | 35762 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2004 | 15 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 592 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2015 | 2025 | 0.050 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2004 | 21 | 0.050 |
Why?
|
| Patient Safety | 2 | 2019 | 347 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2005 | 115 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2008 | 768 | 0.050 |
Why?
|
| Europe | 2 | 2017 | 412 | 0.050 |
Why?
|
| Sample Size | 1 | 2024 | 123 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2005 | 77 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2008 | 537 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2015 | 38 | 0.050 |
Why?
|
| Graft Survival | 2 | 2010 | 526 | 0.050 |
Why?
|
| Pulse Therapy, Drug | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 95 | 0.050 |
Why?
|
| Rats, Mutant Strains | 1 | 2003 | 20 | 0.050 |
Why?
|
| Parturition | 1 | 2004 | 68 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 998 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2003 | 80 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2003 | 93 | 0.050 |
Why?
|
| Physical Examination | 1 | 2005 | 236 | 0.050 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 289 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2003 | 53 | 0.050 |
Why?
|
| Birth Weight | 1 | 2006 | 522 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2004 | 1047 | 0.050 |
Why?
|
| Anesthesia | 1 | 2007 | 257 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3842 | 0.050 |
Why?
|
| Thrombectomy | 1 | 2003 | 77 | 0.050 |
Why?
|
| Capillary Permeability | 1 | 2003 | 134 | 0.050 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 555 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2003 | 90 | 0.050 |
Why?
|
| Thiophenes | 1 | 2003 | 128 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2007 | 407 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 1646 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 2 | 2000 | 93 | 0.050 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2002 | 18 | 0.050 |
Why?
|
| Nitrogen | 1 | 2003 | 170 | 0.050 |
Why?
|
| Computer Simulation | 3 | 2016 | 1025 | 0.040 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2002 | 66 | 0.040 |
Why?
|
| Constriction | 2 | 2003 | 47 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2021 | 21 | 0.040 |
Why?
|
| American Heart Association | 1 | 2023 | 348 | 0.040 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2001 | 13 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 2001 | 37 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 297 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 162 | 0.040 |
Why?
|
| Rats, Inbred Strains | 1 | 2001 | 321 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2003 | 1187 | 0.040 |
Why?
|
| Liver | 1 | 2009 | 1884 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2021 | 213 | 0.040 |
Why?
|
| Angiography | 2 | 1999 | 207 | 0.040 |
Why?
|
| Labor, Obstetric | 1 | 2001 | 66 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2012 | 1739 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1715 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 3157 | 0.040 |
Why?
|
| Ligation | 2 | 2000 | 92 | 0.040 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 34 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 60 | 0.040 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2019 | 12 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2020 | 136 | 0.040 |
Why?
|
| Enzyme Inhibitors | 5 | 2004 | 824 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 1138 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 58 | 0.040 |
Why?
|
| Respiratory Insufficiency | 2 | 2001 | 326 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 80 | 0.040 |
Why?
|
| Gingiva | 1 | 2019 | 25 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2019 | 44 | 0.040 |
Why?
|
| Autografts | 1 | 2019 | 55 | 0.040 |
Why?
|
| Chromosome Deletion | 2 | 2009 | 124 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 69 | 0.040 |
Why?
|
| Blood Circulation | 1 | 1998 | 44 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2000 | 242 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 2019 | 60 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 183 | 0.040 |
Why?
|
| Perfusion | 2 | 2004 | 250 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2019 | 133 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 315 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 98 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2018 | 30 | 0.030 |
Why?
|
| Nose | 1 | 1998 | 68 | 0.030 |
Why?
|
| Myocardium | 1 | 2023 | 939 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 169 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 339 | 0.030 |
Why?
|
| Software | 1 | 2023 | 690 | 0.030 |
Why?
|
| Masks | 1 | 1998 | 70 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2019 | 156 | 0.030 |
Why?
|
| Catheterization | 1 | 1998 | 183 | 0.030 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2018 | 84 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1998 | 117 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2494 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 397 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2019 | 179 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 86 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 1172 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 380 | 0.030 |
Why?
|
| Aftercare | 1 | 2019 | 220 | 0.030 |
Why?
|
| Government Regulation | 1 | 2017 | 38 | 0.030 |
Why?
|
| Child Advocacy | 1 | 2017 | 32 | 0.030 |
Why?
|
| Postoperative Period | 1 | 1998 | 353 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 454 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 151 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2019 | 354 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2017 | 48 | 0.030 |
Why?
|
| Oximetry | 1 | 2018 | 126 | 0.030 |
Why?
|
| Vibration | 1 | 2017 | 71 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2018 | 123 | 0.030 |
Why?
|
| Leg | 1 | 2019 | 239 | 0.030 |
Why?
|
| Policy Making | 1 | 2017 | 82 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2926 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2017 | 84 | 0.030 |
Why?
|
| Swine | 1 | 2019 | 831 | 0.030 |
Why?
|
| Clinical Competence | 2 | 2015 | 1241 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1255 | 0.030 |
Why?
|
| Iron | 1 | 2019 | 359 | 0.030 |
Why?
|
| Estradiol | 1 | 2000 | 533 | 0.030 |
Why?
|
| Aerosols | 1 | 2017 | 186 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 462 | 0.030 |
Why?
|
| Growth Charts | 1 | 2016 | 20 | 0.030 |
Why?
|
| Arginine | 2 | 1994 | 262 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 576 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 406 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 488 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 358 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2019 | 389 | 0.030 |
Why?
|
| Child Health | 1 | 2017 | 157 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 26 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2019 | 301 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 1995 | 15 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2018 | 360 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1997 | 113 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2021 | 869 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 163 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 2015 | 100 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 81 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 401 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2005 | 2525 | 0.030 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2015 | 61 | 0.030 |
Why?
|
| Home Care Services | 1 | 1998 | 280 | 0.030 |
Why?
|
| Rats, Long-Evans | 2 | 2006 | 125 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2021 | 935 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2018 | 5221 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 371 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 575 | 0.030 |
Why?
|
| Acute Disease | 3 | 2005 | 1028 | 0.030 |
Why?
|
| Viper Venoms | 1 | 1994 | 6 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1995 | 311 | 0.030 |
Why?
|
| Aged | 3 | 2020 | 25850 | 0.030 |
Why?
|
| Endothelium | 1 | 1995 | 119 | 0.030 |
Why?
|
| Muscle Tonus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 2154 | 0.030 |
Why?
|
| Length of Stay | 2 | 2012 | 1335 | 0.030 |
Why?
|
| Competency-Based Education | 1 | 2015 | 79 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 1994 | 14 | 0.030 |
Why?
|
| Nifedipine | 1 | 1994 | 27 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 698 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 182 | 0.020 |
Why?
|
| Goals | 1 | 2015 | 180 | 0.020 |
Why?
|
| Alberta | 1 | 2013 | 26 | 0.020 |
Why?
|
| Models, Biological | 1 | 2020 | 1820 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 235 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2013 | 451 | 0.020 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 170 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.020 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2012 | 21 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2015 | 519 | 0.020 |
Why?
|
| Stents | 2 | 2009 | 556 | 0.020 |
Why?
|
| Bronchi | 1 | 2013 | 267 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1406 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2015 | 325 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 527 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2011 | 24 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 138 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 88 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 175 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2143 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 89 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 320 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 370 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2011 | 101 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 508 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2096 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 886 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 768 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 952 | 0.020 |
Why?
|
| Recurrence | 1 | 1994 | 1134 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 307 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2013 | 499 | 0.020 |
Why?
|
| Guanidines | 2 | 2001 | 41 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 2012 | 208 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2010 | 118 | 0.020 |
Why?
|
| Mice | 4 | 2009 | 18329 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1332 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2001 | 162 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2011 | 383 | 0.020 |
Why?
|
| Tricuspid Atresia | 1 | 2008 | 4 | 0.020 |
Why?
|
| Venae Cavae | 1 | 2008 | 7 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 538 | 0.020 |
Why?
|
| Vena Cava, Superior | 1 | 2008 | 25 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 117 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1054 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2009 | 94 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2014 | 709 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 1057 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 177 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2013 | 924 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 363 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1732 | 0.020 |
Why?
|
| Tunica Media | 1 | 2007 | 36 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 2008 | 115 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2007 | 111 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2007 | 67 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 547 | 0.020 |
Why?
|
| Child Development | 1 | 2012 | 484 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 625 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1782 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2005 | 31 | 0.010 |
Why?
|
| Deferoxamine | 1 | 2005 | 25 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1998 | 357 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 5988 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 186 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 76 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2005 | 167 | 0.010 |
Why?
|
| Cross Infection | 1 | 2008 | 262 | 0.010 |
Why?
|
| Reoperation | 1 | 2008 | 629 | 0.010 |
Why?
|
| Common Bile Duct | 1 | 2004 | 14 | 0.010 |
Why?
|
| Compliance | 1 | 2004 | 49 | 0.010 |
Why?
|
| Liver Failure | 1 | 2005 | 83 | 0.010 |
Why?
|
| Protoporphyrins | 1 | 2004 | 14 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 842 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1497 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2015 | 1255 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 402 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 2004 | 66 | 0.010 |
Why?
|
| Hematocrit | 1 | 2004 | 108 | 0.010 |
Why?
|
| Compressive Strength | 1 | 2004 | 72 | 0.010 |
Why?
|
| Tensile Strength | 1 | 2004 | 96 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 938 | 0.010 |
Why?
|
| rho-Associated Kinases | 1 | 2004 | 83 | 0.010 |
Why?
|
| Amides | 1 | 2004 | 101 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 2003 | 25 | 0.010 |
Why?
|
| Hyperoxia | 1 | 2004 | 99 | 0.010 |
Why?
|
| Ventilator Weaning | 1 | 2003 | 39 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 31 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2002 | 52 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 54 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 3119 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1867 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2003 | 162 | 0.010 |
Why?
|
| Waiting Lists | 1 | 2003 | 263 | 0.010 |
Why?
|
| Benzylamines | 1 | 2001 | 42 | 0.010 |
Why?
|
| Amidines | 1 | 2001 | 15 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 459 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 673 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2000 | 68 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 995 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 1182 | 0.010 |
Why?
|
| Pyridines | 1 | 2004 | 605 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 151 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 1495 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 248 | 0.010 |
Why?
|
| Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
|
| Thiazines | 1 | 1998 | 13 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 4146 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1996 | 38 | 0.010 |
Why?
|
| Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
|
| Indomethacin | 1 | 1996 | 76 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 81 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 150 | 0.010 |
Why?
|
| Adenosine | 1 | 1998 | 254 | 0.010 |
Why?
|
| Pressure | 1 | 1996 | 225 | 0.010 |
Why?
|
| Purinones | 1 | 1995 | 4 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1995 | 10 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1995 | 30 | 0.010 |
Why?
|
| Theophylline | 1 | 1995 | 41 | 0.010 |
Why?
|
| Arterioles | 1 | 1995 | 56 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1995 | 82 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1995 | 75 | 0.010 |
Why?
|
| Heart Rate, Fetal | 1 | 1995 | 31 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1993 | 79 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1995 | 553 | 0.010 |
Why?
|